Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 hour 1 min ago

Exact Sciences Appoints Jeff Elliott to Lead Business Development and Strategy

Fri, 06/03/2016 - 13:56
MADISON, Wis., June 3, 2016 -- (Healthcare Sales & Marketing Network) -- Exact Sciences Corp. (EXAS) today announced that Jeff Elliott, a former senior research analyst who covered the diagnostic and lab industries, will join the company as vice president...
Diagnostics, Personnel
EXACT SCIENCES, Cologuard, colorectal cancer

Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer

Fri, 06/03/2016 - 13:38
Phase III study to be initiated in metastatic hormone-sensitive prostate cancer assessing the androgen-receptor antagonist in combination with standard androgen deprivation therapy and the chemotherapy docetaxel Start of patient enrollment expected towa...
Biopharmaceuticals, Oncology
Bayer, Orion Corp, prostate cancer, ARASENS

ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig(R)

Thu, 06/02/2016 - 15:11
Divestiture to Incyte Strengthens Financial Position ARIAD Receives $140 Million Upfront Payment, $135 million to be Received in Potential Oncology Milestones, Tiered Royalty Payments of Between 32% and 50% CAMBRIDGE, Mass.--(Healthcare Sales & Mark...
Biopharmaceuticals, Oncology, Licensing, Acquisitions
ARIAD Pharmaceuticals, Incyte, Iclusig, ponatinib, chronic myeloid leukemia

Juniper Pharmaceuticals Announces Planned Retirement of CEO Frank Condella

Thu, 06/02/2016 - 15:04
BOSTON, June 2, 2016 -- (Healthcare Sales & Marketing Network) -- Juniper Pharmaceuticals, Inc. (JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that Frank C. Condella, Jr., plans to retire as ...
Biopharmaceuticals, Drug Delivery, Personnel
Juniper Pharmaceuticals, intravaginal drug delivery

Occlutech Obtains European CE Mark Approval for its LAA Occluder

Thu, 06/02/2016 - 15:00
SCHAFFHAUSEN, Switzerland, June 2, 2016 -- (Healthcare Sales & Marketing Network) -- Occlutech, a leading innovator of implants to treat structural heart disease, today announced that it has obtained European CE Mark approval for its Left Atrial Appendage...
Devices, Interventional, Cardiology, Regulatory
Occlutech, Left Atrial Appendage

FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer

Thu, 06/02/2016 - 14:55
LAUSANNE, Switzerland, June 2, 2016 -- (Healthcare Sales & Marketing Network) -- Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group™, today announced that the FDA Office of Orphan Products Development (OOPD) has gran...
Biopharmaceuticals, Oncology, FDA
Debiopharm, Debio 1143, ovarian cancer

Aviana Molecular Technologies welcomes William J. Link, Ph.D. as Chairman of its Board of Directors

Wed, 06/01/2016 - 13:46
ORLANDO, Fla., June 1, 2016 -- (Healthcare Sales & Marketing Network) -- Aviana Molecular Technologies, LLC, a development-stage diagnostic company, is very pleased to announce the appointment of Dr. Bill Link as Chairman of its Board of Directors. Dr. L...
Diagnostics, Personnel
Aviana Molecular Technologies

EnteroMedics Announces First-of-its-Kind Procedure with vBloc(R) Therapy Used as Adjunctive Rescue Treatment for Failed Gastric Sleeve in Patients with Obesity

Wed, 06/01/2016 - 13:41
ST. PAUL, Minn., June 1, 2016 -- (Healthcare Sales & Marketing Network) -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced...
EnteroMedics, vBloc , Neurometabolic Therapy

Oncternal Therapeutics Merges with Tokalas to Form Clinical-Stage Biotechnology Company with Promising Oncology Pipeline

Wed, 06/01/2016 - 13:36
Experienced Management Team Appointed to Lead Combined Company to be Oncternal Therapeutics SAN DIEGO, June 1, 2016 -- (Healthcare Sales & Marketing Network) -- Oncternal Therapeutics, Inc. and Tokalas, Inc., today announced that the two companies have...
Biopharmaceuticals, Oncology, Mergers & Acquisitions
Oncternal Therapeutics, Tokalas, Cirmtuzumab, TK216

Elekta’s Leksell Gamma Knife Icon Cleared for Use in Japan and United States

Wed, 06/01/2016 - 13:26
Patients and Clinics to Benefit from Next Generation Stereotactic Radiosurgery System TOKYO and WASHINGTON--(Healthcare Sales & Marketing Network)--Elekta (EKTA-B.ST) announces that Elekta’s Leksell Gamma Knife® Icon™ has been cleared for clinical u...
Devices, Oncology, Neurosurgery, Regulatory
Elekta, Leksell, Gamma Knife Icon, radiosurgery, radiotherapy

Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients

Tue, 05/31/2016 - 14:08
Label Now Includes New Data on Use of TEFLARO in Pediatric Patients 2 Months of Age to Less than 18 Years of Age with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP) TEFLARO is the First Bran...
Biopharmaceuticals, FDA

Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share

Tue, 05/31/2016 - 13:41
Transaction would add VYXEOS™, an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals' portfolio U.S. regulatory submission for VYXEOS planned by end of third quarter 2016 Jazz Pharmaceutica...
Biopharmaceuticals, Oncology, Mergers & Acquisitions
Jazz Pharmaceuticals, Celator Pharmaceuticals, VYXEOS

BioVentrix receives FDA IDE Approval for its Pivotal Clinical Trial, ALIVE

Tue, 05/31/2016 - 13:33
SAN RAMON, Calif., May 31, 2016 -- (Healthcare Sales & Marketing Network) -- BioVentrix Inc., an emerging medical device company for less invasive treatment of heart failure (HF), today announced that it has received a U.S. Food and Drug Administration (F...
Devices, Interventional, Cardiology, FDA
BioVentrix, Revivent TC, TransCatheter, Ventricular Enhancement System

Pixium Vision Receives Clinical Trial Approval from UK Regulatory Authority for 150 Electrode IRIS(R)II Bionic Vision System

Tue, 05/31/2016 - 13:27
World renowned Moorfields Eye Hospital joins the clinical trial for IRIS® II, a bionic vision system equipped with a bio-inspired camera and a 150 electrode epi-retinal implant with an explantable design PARIS, May 31, 2016 -- (Healthcare Sales & Ma...
Devices, Ophthalmology, Regulatory
Pixium Vision, IRIS II, bionic vision, epi-retinal implant

FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union

Mon, 05/30/2016 - 14:13
Biogen to manufacture and commercialize FLIXABI, the company’s second anti-TNF biosimilar therapy in the EU ZUG, Switzerland--(Healthcare Sales & Marketing Network)--The European Commission (EC) today granted marketing authorization in the European Unio...
Biopharmaceuticals, Regulatory
Biogen, FLIXABI, biosimilar, Remicade

Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting

Fri, 05/27/2016 - 13:37
Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016 Webcast with APEX Study Executive Committee Members Today at 11 a.m. ET MONTPELLIER, France, and SOUTH SAN FRANCISCO, Calif. , May 27, 2016 -- (Healthcare Sales & Marketing Net...
Portola Pharmaceuticals, betrixaban, thrombosis

Aclaris Therapeutics Announces $20.0 Million Private Placement

Fri, 05/27/2016 - 13:28
MALVERN, Pa., May 27, 2016 -- (Healthcare Sales & Marketing Network) -- Aclaris Therapeutics, Inc. (ACRS), a clinical-stage specialty pharmaceutical company, announced today that it has entered into a stock purchase agreement with a group of institutional ...
Biopharmaceuticals, Dermatology, Venture Capital
Aclaris Therapeutics, JAK inhibitor

AbbVie's HUMIRA(R) (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision

Fri, 05/27/2016 - 13:20
If approved by the European Commission, HUMIRA would be the first biologic treatment option in the European Union for certain patients with non-infectious intermediate, posterior and panuveitis The opinion is based on results from two pivotal Phase 3 st...
Biopharmaceuticals, Ophthalmology, Regulatory
AbbVie, HUMIRA, adalimumab, uveitis

Acumed Launches New State-of-the-Art System for Ankle Fractures

Thu, 05/26/2016 - 20:55
The Acumed Ankle Plating System 3 is composed of seven plate families that span the lateral, medial, and posterior malleoli. PORTLAND, Ore., May 26, 2016 -- (Healthcare Sales & Marketing Network) -- The Acumed Ankle Plating System 3 and Small Fragment ...
Devices, Orthopaedic, Product Launch
Acumed, Ankle Plating System 3, ankle fracture

New Study Highlights Potential Cost Savings When Using Yttrium-90 Glass Microspheres for Treatment of Hepatocellular Carcinoma

Thu, 05/26/2016 - 15:30
TARE (Transarterial Radio-embolization) Using Yttrium-90 Glass Microspheres, Associated With Both Cost Savings and Overall Decreased Use of Hospital Resource WASHINGTON, May 26, 2016 -- (Healthcare Sales & Marketing Network) -- BTG plc (BTG.L), an inte...
Devices, Oncology
BTG, TheraSphere, Yttrium-90, Microspheres, hepatocellular carcinoma

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong